Terms & Conditions

​

Please read the instructions carefully. We will accept and review only abstracts complying with the instructions below. 

The last day to submit the abstract is March 20th, 2023. 

 

We will accept only abstracts submitted online unless agreed otherwise in advance. 

Upon acceptance of the abstract, the submitting author must register for the conference within seven days following the acceptance notification. Failing to do so will result in the automatic rejection of the abstract.

 

ADIT2023 abstracts awards 

​

ADIT abstract reviewers will select the three best abstracts for the ADIT 2023 award. 

The submitting authors of awarded abstracts will receive the following:

​

• First abstract: 
  Registration plus two (2) nights accommodation to ADIT 2024 

​

• Second and third abstracts: 
  Registration to ADIT 2024.

 

Decisive factors for award selection: 

​

• A value of work and research from the perspective of science. 

• Uniqueness and novelty of the thesis. 

• Importance of abstract to clinical practice in diabetes treatment.  

​

Abstract presentation  

​

The form of the submitted abstract presentation at ADIT2023 is at the sole discretion of abstract reviewers.

• All selected abstracts: publish in the ADIT2023 Program Book 

• Selected abstracts: poster presentation 

• Selected abstracts: oral poster presentation 

• Awarded abstracts: oral presentation during plenary sessions 

​

Terms and conditions for submission 

​

Submitting author must disclose all financial support or commercial interest in the abstract topic upon submission. Abstracts without the disclosure statement will not be accepted. 

Submission of more than one abstract by the same author or submission of identical work by several authors is not allowed. 

Abstracts describing data that have been previously published or submitted and signed by different authors are subject to automatic rejection. 

The submitted abstracts must comply with current ethical standards and regulations in biomedical research. Failure to adhere to these standards will result in the rejection of the abstract.  

​

Content and structure of abstract 

​

• We will accept abstracts related to any topic of diabetes management. 

• The principal author name for the abstract should be that of the author behind the work submitted. 

• Name, Last name, email, and affiliation are mandatory for all abstract authors. 

• The author must submit the abstract in plain text. 

• Do not quote references or include figures, tables, and other images in the abstracts.  

• The body of the abstract must have five (5) sections: Introduction-Methods-Results-Conclusion-Disclosure

• The abstract title must indicate its content accurately. 

• Title maximum length: 250 characters. 

• The abstract body should be no longer than 500 words in length. This limit excludes the abstract title, authors' information, and disclosure. 

• Throughout the abstract, the authors must use non-proprietary names of drugs. The use of commercial drug names will result in automatic rejection.

• For abbreviated words, use the whole term the first time, followed by the standard abbreviation in parenthesis. 

• Organizers will notify only the submitting author of the acceptance or rejection of the abstract.

• If accepted, the abstract's author will receive detailed instructions about the form of the abstract presentation after April 1st, 2023.

 

The authors selected for poster presentation may be required to submit the poster for display in an electronic and traditional poster format.